POLIVY is a CD79b-directed antibody–drug conjugate indicated in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of Polivy (Polatuzumab Vedotin-piiq) brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Polivy (Polatuzumab Vedotin-piiq) medicine cost price in India.
The order for Polivy (Polatuzumab Vedotin-piiq) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Polatuzumab vedotin (brand name Polivy; development codes DCDS4501A and RG7596) is an antibody-drug conjugate or ADC designed for the treatment of cancer. The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab.
POLIVY™ (polatuzumab vedotin-piiq) for injection, for intravenous use. Initial U.S. Approval: 2019
Generic Name: polatuzumab vedotin-piiq
For injection: 140 mg of polatuzumab vedotin-piiq as a lyophilized powder in a single-dose vial.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Polivy (Polatuzumab Vedotin-piiq) on prescription and Import License in Patient's Name only.
For overseas patients, Polivy (Polatuzumab Vedotin-piiq) can be made available in Send your enquiry to find Polivy (Polatuzumab Vedotin-piiq) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
EU Advisory Committee Favors Approval of Polivy with MabThera and Bendamustine for Advanced DLBCL For More Details
FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma For More Details